ד"ר חיה רביצקי מציגה דיון מקרה של מטופלת הסובלת מדיכאון, מחיי הקליניקה היום יומית
בסרטון הקצר מטה, מציגה ד"ר חיה רביצקי דיון מקרה של מטופלת הסובלת מדיכאון, מחיי הקליניקה היום יומית ומדגימה כיצד
CANMAT – הגייד ליין הקנדים – השוואה של פרופיל סבילות בין תרופות נוגדות דיכאון
בסרטון קצר זה, מציג פרופ' מקנטייר את ההנחיות הפרקטיות של ה-CANMAT לשנת 2023 לטיפול בדיכאון ומביא את ההשוואה של
Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study
Highlights Depression and dementia are highly prevalent in older adults and often co-occur. Effectiveness of vortioxetine was assessed in
Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
Abstract Background Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment
Abstract Background Analysis of efficacy and tolerability of vortioxetine 20 mg/day, and optimal timing of dose adjustment, in patients with
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
Abstract Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and usually confer worse treatment outcomes. The
Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment
Highlights • About 50% of MDD patients treated with SSRIs or SNRIs suffer emotional blunting • Emotional blunting has important functional consequences for patients’ daily
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Abstract Purpose Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the
Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study
Abstract Objective: To assess changes in workplace productivity and functioning in an open-label study in working patients receiving vortioxetine (10
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis
Abstract Objective: To evaluate the consistency of vortioxetine's effects on functional capacity in adults with major depressive disorder (MDD)
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study
Abstract Objective: AtWoRC (Assessment in Work productivity and the Relationship with Cognitive symptoms) was an interventional, open-label, Canadian study (NCT02332954)
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma
Abstract Background: This analysis investigates the efficacy of vortioxetine in adults with major depressive disorder (MDD) who report childhood or
The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
Abstract Background: Anhedonia is a common, persistent, and disabling phenomenon in treated adults with Major Depressive Disorder (MDD). Hitherto, relatively
Efficacy of vortioxetine on the physical symptoms of major depressive disorder
Abstract Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with
A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
Abstract Major depressive disorder is a common condition that often includes cognitive dysfunction. A systematic literature review of studies
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
Abstract To investigate the effectiveness, safety, and tolerability of vortioxetine in patients treated at therapeutic doses (5–20 mg/day) for both acute and maintenance treatment,
Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder
Abstract Objectives: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive
Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis
Abstract Objective: Antidepressants are frequently associated with treatment-emergent sexual dysfunction (TESD). Vortioxetine, which was approved for patients with major depressive
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
Abstract The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
Abstract Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs),
Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
Abstract Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
Abstract This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Abstract Objective This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10–20 mg/day) versus agomelatine
Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study
Abstract This double-blind, randomized, placebo- and positive-controlled, parallel-group study evaluated the effect of vortioxetine (Lu AA21004), an investigational multimodal
ד"ר חיה רביצקי מציגה דיון מקרה של מטופלת הסובלת מדיכאון, מחיי הקליניקה היום יומית
בסרטון הקצר מטה, מציגה ד"ר חיה רביצקי דיון מקרה של מטופלת הסובלת מדיכאון, מחיי הקליניקה היום יומית ומדגימה כיצד
CANMAT – הגייד ליין הקנדים – השוואה של פרופיל סבילות בין תרופות נוגדות דיכאון
בסרטון קצר זה, מציג פרופ' מקנטייר את ההנחיות הפרקטיות של ה-CANMAT לשנת 2023 לטיפול בדיכאון ומביא את ההשוואה של
Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study
Highlights Depression and dementia are highly prevalent in older adults and often co-occur. Effectiveness of vortioxetine was assessed in
Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
Abstract Background Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment
Abstract Background Analysis of efficacy and tolerability of vortioxetine 20 mg/day, and optimal timing of dose adjustment, in patients with
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
Abstract Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and usually confer worse treatment outcomes. The
Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment
Highlights • About 50% of MDD patients treated with SSRIs or SNRIs suffer emotional blunting • Emotional blunting has important functional consequences for patients’ daily
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Abstract Purpose Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the
Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study
Abstract Objective: To assess changes in workplace productivity and functioning in an open-label study in working patients receiving vortioxetine (10
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis
Abstract Objective: To evaluate the consistency of vortioxetine's effects on functional capacity in adults with major depressive disorder (MDD)
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study
Abstract Objective: AtWoRC (Assessment in Work productivity and the Relationship with Cognitive symptoms) was an interventional, open-label, Canadian study (NCT02332954)
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma
Abstract Background: This analysis investigates the efficacy of vortioxetine in adults with major depressive disorder (MDD) who report childhood or
The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
Abstract Background: Anhedonia is a common, persistent, and disabling phenomenon in treated adults with Major Depressive Disorder (MDD). Hitherto, relatively
Efficacy of vortioxetine on the physical symptoms of major depressive disorder
Abstract Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with
A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
Abstract Major depressive disorder is a common condition that often includes cognitive dysfunction. A systematic literature review of studies
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
Abstract To investigate the effectiveness, safety, and tolerability of vortioxetine in patients treated at therapeutic doses (5–20 mg/day) for both acute and maintenance treatment,
Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder
Abstract Objectives: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive
Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis
Abstract Objective: Antidepressants are frequently associated with treatment-emergent sexual dysfunction (TESD). Vortioxetine, which was approved for patients with major depressive
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
Abstract The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
Abstract Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs),
Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
Abstract Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
Abstract This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Abstract Objective This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10–20 mg/day) versus agomelatine
Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study
Abstract This double-blind, randomized, placebo- and positive-controlled, parallel-group study evaluated the effect of vortioxetine (Lu AA21004), an investigational multimodal